Lightnews — Scholar-powered news

Ecraid @ecraid.bsky.social · 1d

The #ECDC report on C. auris shows gaps in EU surveillance & IPC. Ecraid is built to fill them:

- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.

We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...

Accelerate Infectious Disease Trials | Ecraid

Accelerate infectious disease research with Ecraid's innovative trial designs and extensive European network for efficient, high-quality clinical trials.

bit.ly

Ecraid @ecraid.bsky.social · 8d

Which antibiotic works best for treating moderate to severe community-acquired pneumonia (CAP) 🫁 ? A commentary in Clinical Microbiology and Infection emphasises the urgent need for stronger evidence - because patients deserve better 👇🏼

@escmid.bsky.social @cmicomms.bsky.social

Marc Bonten @marcbonten.bsky.social · 28d

Now online: our commentary on the topic of initial antibiotic therapy in patients hospitalized with pneumonia. 👇

💣 Spoiler alert: we need to change rules if we want the best therapy for our patients.

www.clinicalmicrobiologyandinfection.org/action/showP...

Empiric antibiotics for moderate-severe community-Acquired Pneumonia: We ought to serve patients better!

Each day thousands of patients are hospitalized worldwide with Community-Acquired Pneumonia (CAP), either radiologically confirmed or presumed based on clinical symptoms only, and each day physicians ...

www.clinicalmicrobiologyandinfection.org

1 1

Ecraid @ecraid.bsky.social · 14d

On 15-SEP, the annual #PNEUMO EU F2F meeting with Ecraid’s operational team and funder MSD took place.
It was a fruitful meeting held at MSD headquarters in Haarlem, with a very nice tour around their facility.
Thanks to Kelly Johnson & #MSD NL for the hospitality & for continuous collaboration!

Ecraid @ecraid.bsky.social · 23d

@academicsky.org @medsky.social @idsky.bsky.social @infectiousdiseases.bsky.social

Ecraid @ecraid.bsky.social · 23d

📩 In our latest newsletter you can read more about Ecraid’s September highlights including studies updates and other milestones!
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: [email protected]

📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...

1

Ecraid @ecraid.bsky.social · Aug 19

🦠 Can respiratory viruses like SARS-CoV-2 and influenza reactivate dormant cancer cells? Although widely regarded as a scientific breakthrough and despite firm conclusions, some emphasised that cancer survivors should not be alarmed yet. Read the latest blog post by @marcbonten.bsky.social

Marc Bonten @marcbonten.bsky.social · Aug 18

Can acute COVID-19 awaken dormant cancer cells?

An important study, recently published.

My blog on the translation of experimental findings in mice to observational population-based data in men. 👇

letstalkscience.eu/2025/08/18/c...

Can acute COVID-19 awaken dormant cancer cells? - Let's Talk Science with Marc Bonten

Yes, according to this study, which was the talk of the summer. In short: In mice experimental lung infection with SARS-CoV-2 and influenza reactivated dormant breast cancer cells, rapidly leading to ...

letstalkscience.eu

1 3

Ecraid @ecraid.bsky.social · Jul 23

Our Education Newsletter is out now! Packed with opportunities and inspiration for early-career researchers and beyond: upcoming postgraduate courses, new scientific papers, a webinar recording you may have missed, & more resources to boost your knowledge 👉 mailchi.mp/ecraid/ecrai...

1 1

Ecraid @ecraid.bsky.social · Jul 14

Don't miss this chance to attend this course featuring insightful lectures, interactive afternoon workshops and invaluable network opportunities with other researchers and experts from across Europe & beyond
👇
www.escmid.org/event-detail...

@escmid.bsky.social @umcutrecht.bsky.social

1

Ecraid @ecraid.bsky.social · Jul 9

We are looking for a visionary Chief Executive Officer to lead Ecraid into its new chapter. If you are a purpose-driven and people-centred leader with bold ideas, an entrepreneurial spirit and a pan-European mindset, we’re looking for you!
More info 👉 www.ecraid.eu/careers

1

Ecraid @ecraid.bsky.social · Jul 8

@idsky.bsky.social @academicsky.org @medsky.social

Ecraid @ecraid.bsky.social · Jul 8

📩In our latest newsletter you can read more about our upcoming educational opportunities and get the latest updates on publications and study milestones.

👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.

📫Stay informed, subscribe now: bit.ly/07NewsEcraid

1

Ecraid @ecraid.bsky.social · Jul 7

What are ethical, administrative, regulatory and logistical hurdles for delivery of RCTs & can these be qualified? Hot off the presses, this article in @jamanetworkopen.com by [email protected], the REMAP-CAP investigators & the Ecraid operational team: jamanetwork.com/journals/jam...

1 1

Ecraid @ecraid.bsky.social · Jul 3

Very pleased to announce a new speaker at our 'Better Methods' course in Athens: Prof. Sotirios Tsiodras! The programme will be updated shortly to reflect his topic.
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...

Ecraid @ecraid.bsky.social · Jun 26

💡New publication!
Researchers from #ECRAIDBase and ADVANCE-ID (NUS) have co-authored an article analysing the Personalised Randomised Controlled Trial (#PRACTicalTrial) design.
📖 bit.ly/45GgWUT
#ResearchCollaboration #HORIZON2020
@advance-id.bsky.social @horizoneu.bsky.social @hug-ge.bsky.social

Ecraid @ecraid.bsky.social · Jun 18

@escmid.bsky.social @gardp.bsky.social @jesusrbano.bsky.social‬ @mariskaleeflang.bsky.social

1

Ecraid @ecraid.bsky.social · Jun 18

#DKY that in our post-grad course you can choose between two tracks, join parallel workshops, discuss real-world cases, & network with your peers? 💡

👀Check out the programme, apply for an attendance grant, or register directly to secure your place!

➡️ bit.ly/44a1tdn

#IDSky #ResearchSky #Education

1 1 2

Ecraid @ecraid.bsky.social · Jun 13

Proud of our partners at University of Geneva for having published an ECRAID-Base article investigating additional analysis methods for the novel Personalised Randomised Controlled Trial (PRACTical) design in @springernature.com:

👉 www.ecraid.eu/projects/ecr...

1 2

Ecraid @ecraid.bsky.social · Jun 11

REMAP-CAP has published a paper in @springernature.com's Intensive Care Medicine Journal investigating whether hydrocortisone improves mortality in severe community-acquired pneumonia 👉 link.springer.com/article/10.1...
#Pneumonia #ClinicalTrials #REMAPCAP

1

Ecraid @ecraid.bsky.social · Jun 10

@academicsky.org @idsky.bsky.social @infectiousdz.bsky.social #ClinicalResearch #InfectiousDiseases #NewCollaborations #Education #KnowledgeSharing

Ecraid @ecraid.bsky.social · Jun 10

📩Check our latest newsletter for: highlights from our recent meeting with key primary care representatives, new collaborations (VAC4EU) and upcoming educational opportunities.
👉🏽Registration is open for the Postgraduate course in Athens!

📫Stay informed, subscribe now: bit.ly/EcraidJune25

1 1

Ecraid @ecraid.bsky.social · Jun 10

@academicsky.org @infectiousdiseases.bsky.social @idsky3.bsky.social #ClinicalResearch #InfectiousDiseases #NewCollaborations #Education #KnowledgeSharing

Ecraid @ecraid.bsky.social · May 30

#warmbasenetwork #hospitalnetwork #clinicalresearch

Ecraid @ecraid.bsky.social · May 30

Diagnosing & treating infections in #ICUs is complex due to the need for rapid intervention and growing antibiotic resistance. Our head of CLIN-Net Miranda Hopman is at the Intensive Medicine Congress in Lisbon to discuss future collabos & share expertise on building a 'warm-base' research network.

2 1

Ecraid @ecraid.bsky.social · May 29

Join this webinar organised by Ecraid & the European Respiratory Society, tackling adaptive clinical trials designs in the setting of a respiratory infection.

Info & registration 👉 ecraid.eu/news/webinar...

This webinar concludes the Ecraid Training Modules on Adaptive Clinical Trial Designs.

1 1 1

Ecraid @ecraid.bsky.social · May 28

👩‍🍼 Every year, ~400k babies in Europe are born preterm and require admission to a NICU. Ecraid is proud to be part of the #NeoDeco study, which aims to determine if optimised #kangaroocare can reduce resistant bacterial colonization, severe #neonatalinfections and #sepsis in preterm infants in NICUs.

Penta Foundation @pentafoundation.bsky.social · May 15

For many parents, the #NICU is an unexpected world of beeping monitors, quiet strength & waiting.

On #KangarooCareAwarenessDay, we’re proud to launch “NICU Journeys”, a new #NeoIPC series sharing parents’ stories, hope & the power of #KangarooCare & #IPC.

Watch ➡ neoipc.org/updates/stor...

1 1